For instance, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can enhance the anti-tumor immune response by blocking inhibitory signals that dampen T cell activity, thereby promoting apoptosis of cancer cells. Here, PDCD1 is linked to neoplasm.